Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Blood|January 17, 2013
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic targetIl-Kyoo Park, Anjali Mishra, Jason Chandler, et al.
Biopharmaceutics & Drug Disposition|October 10, 2014
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patientsScott M Hynes, Enaksha Wickremsinhe, Wei Zhang, et al.
Cancers|February 6, 2021
<i>TP53</i> Mutations as a Driver of Metastasis Signaling in Advanced Cancer PatientsRitu Pandey, Nathan Johnson, Laurence Cooke, et al.
Medical Physics|January 7, 2003
Verification of multileaf collimator leaf positions using an electronic portal imaging deviceSanjiv S Samant, Wei Zheng, Nestor Andres Parra, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2018
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)David R Spigel, Craig Reynolds, David Waterhouse, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2018
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153David Waterhouse, Leora Horn, Craig Reynolds, et al.
The Lancet. Oncology|April 5, 2017
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trialJames L Gulley, Arun Rajan, David R Spigel, et al.
Oncology|June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid TumorsDavid Hong, Drew Rasco, Michael Veeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2020
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153David M Waterhouse, Edward B Garon, Jason Chandler, et al.
Pageof 1